-
1.发明授权公开(公告)号：US06326163B1
公开(公告)日：2001-12-04
申请号：US09147404
申请日：1999-04-06
IPC分类号： C12Q100
CPC分类号： G01N33/6818 , G01N30/7233 , G01N33/6887 , G01N2333/4712 , Y10S435/968
摘要： The present invention relates to a quick method for the qualitative and quantitative medical-diagnostic analysis on the protein level of the substitution of single amino acids with pathogenic and non-pathogenic effects on the organism. The medical-diagnostic analysis is performed by a combination of enzymatic or chemical cleavage of the isolated peptide, chromatographical separation of the fragments and analysis by mass spectrometry, both direct LC/MS and indirect MALDI-MS, and analysis by capillary electrophoresis. By comparing protein samples from healthy humans with those of ill humans, the method described is suitable for establishing new, as yet unknown mutations and quantifying the expression and incorporation of wild type to mutant.
摘要翻译： 本发明涉及一种用于对单个氨基酸取代的蛋白质水平进行定性和定量医学诊断分析的快速方法，其对生物具有致病和非致病作用。 医学诊断分析通过分离的肽的酶或化学切割，片段的色谱分离和质谱分析，直接LC / MS和间接MALDI-MS的分析以及毛细管电泳分析来进行。 通过比较来自健康人类的蛋白质样品与不良人类的蛋白质样品，所述方法适用于建立新的尚未知的突变并定量野生型与突变体的表达和结合。
-
公开(公告)号：US06579849B2
公开(公告)日：2003-06-17
申请号：US09155203
申请日：1998-09-24
IPC分类号： A61K3800
CPC分类号： A23L3/3463 , A61K38/00 , C07K14/4732
摘要： A peptide having the amino acid sequence H2N—X1—R—X3—X2—COOH (formula I) wherein X1 is either zero or X1 and/or X2 are a residue representing at least five amino acid residues (symbolized in the one letter amino acid code), preferably naturally occurring amino acids, with the proviso that X1 and/or X2 contain at least one basic amino acid residue immediately followed by a hydrophobic amino acid residue and X1 and/or X2 contain at least one glutamine residue.
摘要翻译： 具有其中X 1的氨基酸序列的肽是零或X 1和/或X 2是代表至少5个氨基酸残基的残基（在一字母氨基酸代码中表示），优选天然存在的氨基酸，条件是X 1和/或X 2 含有至少一个碱性氨基酸残基，紧接着是疏水性氨基酸残基，X 1和/或X 2含有至少一个谷氨酰胺残基。
-
3.发明申请Human chondroosteomodulin (tig2), production, and use for the treatment or diagnosis of bone diseases, cartilage diseases, cartilage diseases, obesity, inflammatory diseases, and skin diseases 审中-公开人软骨调蛋白（tig2），生产和用于治疗或诊断骨病，软骨疾病，软骨疾病，肥胖症，炎性疾病和皮肤病公开(公告)号：US20060100145A1
公开(公告)日：2006-05-11
申请号：US10533300
申请日：2003-10-24
申请人： Wolfgang Meder , Martin Wendland , Harald John , Rudolf Richter , Markus Meyer , Wolf-Georg Forssmann
发明人： Wolfgang Meder , Martin Wendland , Harald John , Rudolf Richter , Markus Meyer , Wolf-Georg Forssmann
IPC分类号： A61K38/22 , C40B40/10 , C07K14/575
CPC分类号： C07K14/705 , C07K14/47 , C07K14/51
摘要： The invention relates to the polypeptide COM and its derivatives, and methods for its preparation and recovery in a pure or partially purified form from body fluids and tissues, and its use as a medicament.
摘要翻译： 本发明涉及多肽COM及其衍生物及其制备和从体液和组织中纯化或部分纯化形式的回收方法及其作为药物的用途。
-
4.发明授权Use of urodilatin for treating chronic kidney failure with residual kidney functions 有权使用尿路清蛋白治疗慢性肾功能衰竭与残留肾功能公开(公告)号：US06831064B1
公开(公告)日：2004-12-14
申请号：US10088498
申请日：2002-07-18
IPC分类号： A61K3800
CPC分类号： A61K38/2242
摘要： Use of urodilatin for treating chronic renal insufficiency by stimulating the residual renal function.
摘要翻译： 用尿激酶治疗慢性肾功能不全通过刺激残留的肾功能。
-
5.发明授权HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof 失效HPTH片段 - （1-37），其制备方法，含有其的药物及其用途
公开(公告)号：US5744444A
公开(公告)日：1998-04-28
申请号：US440117
申请日：1995-05-12
IPC分类号： A61K38/00 , C07K14/635 , A61K38/17 , C07K4/635
CPC分类号： C07K14/635 , A61K38/00
摘要： The invention relates to a peptide from human blood, designated as hPTH-(1-37), the structure of which was elucidated for the purpose of the diagnostic, medical and commercial utilization thereof. The isolation of a fragment hPTH-(38-84) proves the existence of the hPTH-(1-37). A removal of amino-terminal amino acids from the hPTH fragment-(1-37) reduces its biological activity. The hPTH-(1-37) circulating in the blood is identical with the synthetic reference substance hPTH-(1-37), however not with fragments such as hPTH-(1-33), hPTH-(1-34) or hPTH-(1-38). The molecule form hPTH-(1-37) has been proven by mass spectrometry (plasma desorption method). A different biological activity and differences in the three-dimensional peptide structure of the hPTH fragment-(1-37) in comparison to other hPTH fragments furnish evidence of that this fragment is the preferential natural peptide of the parathormone family which should be used for the treatment of diseases of the parathyroid, circulatory system, respiratory system, male genital organ and kidneys.
摘要翻译： 本发明涉及一种称为hPTH-（1-37）的人血液肽，其结构用于诊断，医学和商业应用的目的。 片段hPTH-（38-84）的分离证明了hPTH-（1-37）的存在。 从hPTH片段（1-37）去除氨基末端氨基酸降低其生物活性。 在血液中循环的hPTH-（1-37）与合成参考物质hPTH-（1-37）相同，但不与hPTH-（1-33），hPTH-（1-34）或hPTH - （1-38）。 分子形式的hPTH-（1-37）已经通过质谱法（血浆解吸法）证实。 与其他hPTH片段相比，hPTH片段（1-37）的三维肽结构的不同生物活性和差异提供了证据，证明该片段是parathormone家族的优选天然肽，其应用于 治疗甲状旁腺，循环系统，呼吸系统，男性生殖器官和肾脏的疾病。
-
公开(公告)号：US5665861A
公开(公告)日：1997-09-09
申请号：US480359
申请日：1995-06-07
CPC分类号： C07K14/58 , A61K38/00 , Y10S530/834
摘要： Described is a peptide fragment which comprises the amino acid sequence 95-126 of ANF/CDD 1-126 (gamma-hANaP) and is formed in the kidney. The fragment urodilatin (ANF/CDD 95-126) has the following amino acid sequence: ##STR1## wherein R.sup.1 and R.sup.2 each represent further peptide fragments of ANF/CDD 1-126 (gamma-hANaP). In the amino acid sequence R.sup.1 is Thr-Ala-Pro-Arg-Ser-Leu-Arg-Arg-Ser-Ser and R.sup.2 is Asn-Ser-Phe-Arg-Tyr. Further described are processes for the preparation and/or recovery of the new peptide fragment and a medicament containing urodilatin (ANF/CDD 95-126) as well as medical indications of the medicament.
摘要翻译： 描述了包含ANF / CDD 1-126（γ-hANaP）的氨基酸序列95-126并形成于肾中的肽片段。 片段尿苷酶（ANF / CDD 95-126）具有以下氨基酸序列：其中R1和R2各自代表ANF / CDD 1-126（γ-hANaP）的另外的肽片段。 在氨基酸序列中，R1是Thr-Ala-Pro-Arg-Ser-Leu-Arg-Arg-Ser-Ser，R2是Asn-Ser-Phe-Arg-Tyr。 还描述了用于制备和/或回收新肽片段的方法和含有尿布洛林（ANF / CDD 95-126）的药物以及药物的医学适应症。
-
公开(公告)号：US5571789A
公开(公告)日：1996-11-05
申请号：US335695
申请日：1994-11-15
CPC分类号： A61K38/2242
摘要： The present invention relates to the use of a pharmaceutic composition containing urodilatin as an active substance and optionally pharmaceutically usual diluents, excipients, fillers or adjuvants for treating pulmonary and/or bronchial diseases.
摘要翻译： PCT No.PCT / EP93 / 01189第 371日期：1994年11月15日 102（e）1994年11月15日日期PCT提交1993年5月12日PCT公布。 公开号WO93 / 23070 日期：1月25日，1993本发明涉及含有尿布菌素作为活性物质的药物组合物和任选药学上常用的稀释剂，赋形剂，填充剂或佐剂用于治疗肺和/或支气管疾病的用途。
-
公开(公告)号：US20140328900A1
公开(公告)日：2014-11-06
申请号：US14234919
申请日：2012-08-03
IPC分类号： C07K14/64
摘要： A process for preparing human relaxin-2 having the following amino acid sequence:A chain: (SEQ ID NO: 1) pGlu-Leu-Tyr-Ser-Ala-Leu-Ala-Asn-Lys-Cys-Cys-His- Val-Gly-Cys-Thr-Lys-Arg-Ser-Leu-Ala-Arg-Phe-Cys B chain: (SEQ ID NO: 2) Asp-Ser-Trp-Met-Glu-Glu-Val-Ile-Lys-Leu-Cys-Gly- Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Cys-Gly- Met-Ser-Thr-Trp-Ser; comprising the following steps:providing the amino acids necessary for the synthesis of the A and B chains with usual protective groups, wherein the cysteines are employed as trityl-protected amino acids (L-Cys(Trt)-OH);effecting a chromatographic purification of the individual chains A and B after the solid state synthesis;followed by the simultaneous folding and combination of the individual chains A and B in ammonium hydrogencarbonate buffer at pH 7.9 to 8.4; andsubsequent purification of the relaxin-2 formed.
摘要翻译： 具有以下氨基酸序列的人松弛素-2的制备方法：A链：（SEQ ID NO：1）pGlu-Leu-Tyr-Ser-Ala-Leu-Ala-Asn-Lys-Cys-Cys-His-Val -Gly-Cys-Thr-Lys-Arg-Ser-Leu-Ala-Arg-Phe-Cys B链：（SEQ ID NO：2）Asp-Ser-Trp-Met-Glu-Glu-Val-Ile-Lys- Leu-Cys-Gly-Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Cys-Gly-Met-Ser-Thr-Trp-Ser; 包括以下步骤：用通常的保护基提供合成A和B链所必需的氨基酸，其中半胱氨酸用作三苯甲基保护的氨基酸（L-Cys（Trt）-OH））; 在固态合成后进行单链A和B的色谱纯化; 然后在pH 7.9至8.4的同时折叠和组合各个链A和B在碳酸氢铵缓冲液中; 并随后纯化形成的松弛素-2。
-
9.发明申请USE OF URODILATIN FOR PREPARING A MEDICAMENT FOR THE TREATMENT OF CARDIOVASCULAR, RENAL, PULMONARY AND NEURONAL SYNDROMES WHILE AVOIDING A REBOUND 审中-公开用于制备用于治疗心脏病，肾脏，肺动脉和神经综合征的药物的URODILATIN的用途公开(公告)号：US20130197188A1
公开(公告)日：2013-08-01
申请号：US13635339
申请日：2011-03-15
申请人： Wolf-Georg Forssmann
发明人： Wolf-Georg Forssmann
IPC分类号： A61K38/22
CPC分类号： A61K38/22 , A61K9/0019 , A61K38/2242 , A61K47/26
摘要： Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound, wherein said medicament for the delivery of urodilatin is suitable in a first quantity for a first period of at least 48 hours, followed by delivery over a second period of at least 12 hours with successive reduction of said first quantity continuously or gradually to 0 ng/kg/min.
摘要翻译： 使用尿路清蛋白制备用于治疗心血管，肾，肺和神经元综合征的药物，同时避免反弹，其中所述用于递送尿布药的药物适于第一次至少48小时的第一期，其次是 在第二期至少12小时内递送，连续或逐渐地将所述第一量连续减少至0ng / kg / min。
-
公开(公告)号：US07732406B2
公开(公告)日：2010-06-08
申请号：US11400696
申请日：2006-04-07
IPC分类号： A61K38/17
CPC分类号： A61K38/2242 , A61K47/26
摘要： The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.
摘要翻译： 本发明涉及尿钠肽如尿d素用于治疗患有心力衰竭的患者，例如急性失代偿性心力衰竭。 优选地，将包含有效量的尿布菌素的组合物在至少24小时和至多120小时，优选至少48小时的持续时间内静脉内施用于患者。
-
-
-
-
-
-
-
-
-
搜索结果
54 条记录 (耗时 0.023 秒)
